Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Overt hepatic encephalopathy ( (very low certainty).
1 finding from 1 review
Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review
Elevated alanine aminotransferase · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Elevated total bilirubin · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to higher complete response plus partial response Length of compared with TACE alone (low certainty).
1 finding from 1 review
Elevated alanine aminotransferase Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated alanine aminotransferase Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Elevated total bilirubin Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated total bilirubin Length of compared with TACE alone (very low certainty).
1 finding from 1 review
All‐cause mortality (at 1 year) · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) changes all‐cause mortality (at 1 year) compared with transarterial chemoembolisation (TACE) (very low certainty).
1 finding from 1 review
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Cholecystectomy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review
Liver transplantation · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes liver transplantation compared with placebo (very low certainty).
1 finding from 1 review
Malignancy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found